Publication: The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review
Issued Date
2013-10-08
Resource Type
ISSN
1593098X
0392856X
0392856X
Other identifier(s)
2-s2.0-84883774149
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Experimental Rheumatology. Vol.31, No.SUPPL.76 (2013)
Suggested Citation
Chayawee Muangchan, Janet Elizabeth Pope The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review. Clinical and Experimental Rheumatology. Vol.31, No.SUPPL.76 (2013). Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/31856
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review
Author(s)
Other Contributor(s)
Abstract
Objectives. Interleukin-6 (IL-6) may play a role in the pathogenesis of SSc. C-reactive protein (CRP), an acute phase reactant induced by IL-6, may be a prognostic marker in SSc. The goal of this systematic review was to address the significance and clinical application of IL-6 and CRP in systemic sclerosis (SSc). Methods. A literature search was conducted to identify English-language original articles within PubMed, Scopus, and Medline database from inception to May 30, 2013 using keywords "systemic sclerosis or scleroderma and C-reactive protein or interleukin-6". Results. The search resulted in 156 relevant articles. Some single nucleotide polymorphisms and gene-gene interactions affect SSc predisposition, manifestation and expression of IL-6. Studies in animal models show IL-6 and IL-6 trans-signalling are involved in SSc disease development. Derangements of T and B cells function regulate IL-6 in SSc pathogenesis. Fibroblasts, T/B cells, monocytes, macrophages, dendritic cells and endothelial cells participate in IL-6 expression and interact with each other resulting in tissue sclerosis. Up-regulation of serum IL-6 and CRP levels are evident in SSc patients and associated with disease activity, severity, disability, worse outcome and reduced survival. Targeted IL-6 therapy in SSc has occurred in small cases series and within a multi-site trial that is under way. Conclusions: Studies show IL-6 and CRP are important in SSc both in pathogenesis and clinical manifestations and may be useful indicators of disease activity, severity, and poor prognosis. IL-6 could be a relevant treatment target in SSc. © Clinical and Experimental Rheumatology 2013.